– U.S. Regulatory Filing Under Active Review for Approval of PYRUKYND® (mitapivat) in Thalassemia, with PDUFA Goal Date of September 7, 2025 – – Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease On Track, with Topline Results Expected in Late 2025; Potential U.S. Commercial Launch in 2026 – – Tebapivat Advancing in Clinical Trials for Lower-Risk Myelodysplastic Syndromes (LR-MDS) and Sickle Cell Disease – – PYRUKYND Net Revenue of $8.7 Million in Q1; Cash, Cash Equivalents and Marketable Securities ...

First quarter consolidated revenues were $3.8 billion on lower industry demand First quarter diluted EPS at $0.10 Results reflect continued execution of cost saving initiatives partially offsetting market headwinds Updated guidance reflects macroeconomic uncertainty from the global trade environment Basildon, UK - May 1, 2025 - CNH Industrial N.V. (NYSE: CNH) today reported results for the three months ended March 31, 2025, with net income of $132 million and diluted earnings per share of $0.10 compared wit ...

Expect to place approximately $8.5 billion of projects into service in 2025, tracking to roughly 15 per cent under budget Announced $2.4 billion of new natural gas and nuclear power generation growth projects CALGARY, Alberta, May 01, 2025 (GLOBE NEWSWIRE) -- TC Energy Corporation (TSX, NYSE: TRP) (TC Energy or the Company) released its first quarter results today. François Poirier, TC Energy’s President and Chief Executive Officer commented, "As natural gas and electricity are forecasted to drive the major ...

Phoenix, AZ, May 01, 2025 (GLOBE NEWSWIRE) -- InnSuites Hospitality Trust (NYSE American: IHT) reported annual results with continued revenue growth in Fiscal Year 2025, (February 1, 2024, to January 31, 2025), with Total Revenues increasing to approximately $7.6 million, a further increase from the prior Fiscal Year total. IHT hotel operations were strong in the 2025 Fiscal Year ended January 31, 2025. Both the Tucson Hotel and Albuquerque Hotel also achieved excellent results for the combined months of Fe ...

Coloplast revises financial guidance for FY 2024/25 and pre-announces H1 2024/25 key financial figures Coloplast revises the guidance on organic growth and EBIT margin before special items for FY 2024/25. The organic growth is now expected to be around 7%, from previously 8-9%. The EBIT margin before special items is now expected to be 27-28%, from previously around 28%. Key financial figures and developments in Q2: Group organic growth was 6% in Q2. The EBIT margin before special items was 27%.Organic gro ...

ATLANTA, May 1, 2025 /PRNewswire/ -- Graphic Packaging Holding Company (NYSE: GPK) ("Graphic Packaging", or "the Company"), a global leader in sustainable consumer packaging, today announced that its Board of Directors has approved a new $1.5 billion share repurchase authorization. This authorization is in addition to the July 27, 2023 share repurchase authorization under which $365 million remains available, bringing the aggregate available authorization as of April 30, 2025 to $1.865 billion.The new autho ...

Key Information - The exempt principal trader involved is Investec Bank plc [1] - The offeror/offeree related to the securities is GlobalData plc [1] - The date of the dealings was April 30, 2025 [1] Dealings by the Exempt Principal Trader - Purchases: 2,010,104 ordinary securities were purchased at a highest price of 180 and a lowest price of 137.5 [3] - Sales: 2,055,036 ordinary securities were sold at a highest price of 175.5 and a lowest price of 137.5 [3] Other Information - There are no indemnity or option arrangements related to the relevant securities [8] - There are no agreements or understandings regarding voting rights or future acquisition/disposal of relevant securities [9] - The date of disclosure for this information is May 1, 2025 [9]

Core Insights - X4 Pharmaceuticals is making significant progress in its Phase 3 clinical trial for mavorixafor, targeting chronic neutropenia, with full enrollment expected by Q3 or Q4 2025 and top-line data anticipated in the second half of 2026 [1][5] - The company has generated $3.5 million in net U.S. revenues from XOLREMDI since its launch in May 2024, indicating a positive market response [1][4] - A strategic restructuring is underway to optimize the promotion of XOLREMDI and focus on mavorixafor, with expected annual savings of $30-35 million [6] Financial Performance - For Q1 2025, X4 reported net revenue of $28.8 million, with $27.9 million from license and other revenues and $0.9 million from product revenue [10][20] - Research and Development (R&D) expenses decreased to $18.5 million from $19.9 million in Q1 2024, while Selling, General, and Administrative (SG&A) expenses also fell to $15.0 million from $17.4 million [10][20] - The company achieved a net income of $0.3 million in Q1 2025, a significant improvement from a net loss of $51.8 million in the same period of 2024 [10][20] Clinical Developments - The 4WARD trial is a pivotal Phase 3 study evaluating mavorixafor in patients with chronic neutropenia, aiming to demonstrate significant increases in absolute neutrophil count (ANC) and reductions in infection rates [5][15] - Recent analyses of clinical trial data have bolstered confidence in the potential success of the 4WARD trial, suggesting that mavorixafor may effectively elevate ANC and reduce infection rates [5] - X4 has received a Notice of Allowance for a patent related to mavorixafor, which is expected to expire in March 2041, enhancing the company's intellectual property position [5] Market Expansion - X4 has entered into two international partnerships for the commercialization of mavorixafor, expanding its global reach [9] - The Marketing Authorization Application (MAA) for mavorixafor in the treatment of WHIM syndrome has been validated for review by the European Medicines Agency, with potential approval in the first half of 2026 [9] Stock and Cash Position - As of March 31, 2025, X4 had a cash position of $87.7 million, which is expected to support operations into the first half of 2026 [10] - A one-for-thirty reverse stock split was executed on April 28, 2025, reducing the number of outstanding shares significantly [7]

Core Insights - Tri Pointe Homes announced two new land acquisitions in South Carolina as part of its Coastal Carolinas division, focusing on single-family homes in Bluffton and townhomes in Beaufort, reflecting the company's strategy to cater to diverse homebuyers [1][2] Group 1: Company Strategy and Vision - The acquisitions are seen as a significant milestone for Tri Pointe Homes, with CEO Doug Bauer emphasizing the opportunity to contribute to the thriving community of Beaufort County, known for its longevity, education, and prosperity [2] - The Coastal Carolinas division is positioned to deliver premium lifestyle experiences through innovative design and strong community ties, aiming to establish itself as a leading brand in a high-growth market [5] Group 2: Project Details - The Bluffton project, expected to be completed by 2027, will feature single-family rear-load homes designed to blend modern convenience with local charm, located near downtown Bluffton's amenities and top-rated schools [3] - The Beaufort project, also anticipated for 2027, will include townhomes with Lowcountry-inspired architecture, providing residents with access to shopping, dining, and educational facilities, as well as proximity to the Broad River waterfront [4] Group 3: Company Background - Tri Pointe Homes is one of the largest homebuilders in the U.S., operating in 12 states and recognized for its customer experience, innovative design, and environmentally responsible practices [6] - The company has received multiple accolades, including Builder of the Year and Developer of the Year, and has been listed among Fortune's Most Admired Companies and Best Companies to Work For [6][7]

Core Viewpoint - Oaktree Specialty Lending Corporation reported a decline in financial performance for the second fiscal quarter of 2025, primarily due to lower investment income and challenges with certain portfolio investments [3][4][11]. Financial Performance - Total investment income for the second fiscal quarter of 2025 was $77.6 million ($0.90 per share), down from $86.6 million ($1.05 per share) in the first fiscal quarter [4][11]. - Adjusted total investment income was $77.2 million ($0.90 per share) for the second quarter, compared to $87.1 million ($1.06 per share) in the previous quarter [4][11]. - GAAP net investment income decreased to $39.1 million ($0.45 per share) from $44.3 million ($0.54 per share) in the prior quarter [4][11]. - Net asset value (NAV) per share fell to $16.75 as of March 31, 2025, down from $17.63 as of December 31, 2024, reflecting losses on certain investments [4][11]. Investment Activity - The company originated $407.0 million in new investment commitments and received $279.4 million from prepayments and exits during the quarter [4][12]. - The weighted average yield on new debt investments was 9.5% [4][12]. - As of March 31, 2025, the fair value of the investment portfolio was $2.9 billion, consisting of investments in 152 companies [12][16]. Debt and Liquidity - Total debt outstanding was $1,470.0 million, with a total debt to equity ratio of 1.00x and a net debt to equity ratio of 0.93x [4][26]. - Liquidity included $97.8 million in unrestricted cash and over $1.0 billion in undrawn capacity under credit facilities [4][24]. - The company issued $300 million in unsecured notes during the quarter, maturing on February 27, 2030, with an interest rate of 6.340% [4][23]. Distributions - A quarterly cash distribution of $0.40 per share and a supplemental distribution of $0.02 per share were declared, payable on June 30, 2025 [5][6]. Portfolio Composition - As of March 31, 2025, 94.9% of the portfolio at fair value consisted of debt investments, with 80.9% in first lien loans [17][18]. - The number of portfolio companies increased to 152 from 136 as of December 31, 2024 [12][17]. Recent Developments - On April 8, 2025, the company amended its senior secured credit facility, reducing interest rate margins and extending the maturity date [27]. Management Commentary - The CEO emphasized the focus on resolving challenges with certain portfolio investments and diversifying the portfolio to capitalize on market opportunities amid economic uncertainty [3][5].